Search for:
  • Sign in
  • Register
  • Country Reports
  • Interviews
  • InFocus
  • Europe
  • Asia-Pacific
  • Americas
  • Middle East & Africa
  • Legal & Regulatory
  • Facts & Figures
  • Library
  • Op-eds
  • Shop
Tuesday, June 10, 2025
PharmaBoardroom
Sign In Register
  • Home
  • Country Reports
    • All
    • Americas
    • Asia-Pacific
    • Europe
    • Middle East & Africa
  • Exclusive interviews
    • All
    • Latest
    • Americas
    • Asia-Pacific
    • Europe
    • Middle East & Africa
  • Articles
    • All
    • Global
    • Latest
  • Legal & Regulatory
    • All
    • The Pharma Legal Handbook
    • Regulatory, Pricing and Reimbursement
    • Marketing, Manufacturing, Packaging and Labeling
    • Preclinical and Clinical Trials
  • Op-Eds & Contributions
  • InFigures
    • All
    • Rankings
    • Americas
    • Asia-Pacific
    • Europe
    • Middle East & Africa
  • Library
    • All
    • InFocus
    • InFigures
    • White Papers
  • Media Kit
  • Register
  • About Us
  • Country Reports
  • Interviews
  • InFocus
  • Europe
  • Asia-Pacific
  • Americas
  • Middle East & Africa
  • Legal & Regulatory
  • Facts & Figures
  • Library
  • Op-eds
  • Shop
Poland Pharma Report 2018 Download

Poland,

May 2018

With GDP growth at 4.6% for 2017, pharma market growth of 4.2%, 38 million people, and a strategic location in the center of Europe, Poland has solid foundations for success in healthcare and the life sciences. The situation is improving for both generics companies and innovators and there are plans to increase public health expenditure to 6% by 2025.

 

Multinational companies are flocking to Poland to establish manufacturing sites, global shared service centers and clinical trials facilities. Domestic generics players continue to perform well – with some now possessing the means and expertise to move into biologics. This report touches on all the main themes currently at play in the industry through the exclusive insights of some of its major players.

With GDP growth at 4.6% for 2017, pharma market growth of 4.2%, 38 million people, and a strategic location in the center of Europe, Poland has solid foundations for success in healthcare and the life sciences. The situation is improving for both generics companies and innovators and there are plans to increase public health expenditure to 6% by 2025.

 

Multinational companies are flocking to Poland to establish manufacturing sites, global shared service centers and clinical trials facilities. Domestic generics players continue to perform well – with some now possessing the means and expertise to move into biologics. This report touches on all the main themes currently at play in the industry through the exclusive insights of some of its major players.

See more

Legal & Regulatory

report
Buy
Tags:
Poland, Pharma, Report, Healthcare, Life Sciences
Share on Facebook Share on WhatsApp Share on Twitter Share on Linkedin Share in Email
Back
PharmaBoardroom

PharmaBoardroom Limited
Evolution House
Iceni Court, Delft Way,
Norwich, NR6 6BB UK

Latest

  • Articles
  • In Conversation
  • Facts & Figures
  • Country Reports
  • Legal & Regulatory
  • InFocus

More

  • About Us

Join Us

  • Email Newsletters
  • LinkedIn

Contact

+44 2078673717

info@stage.pharma.kalyna.dev

Legal & Privacy

  • Terms and Conditions
  • Privacy and Cookies policy
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here

logo

Sign in

Forgot password? Register Now